Core Points - Armory Mining Corp. has successfully closed the second and final tranche of its oversubscribed non-brokered private placement offering, raising a total of $853,000 [1][3] - The final tranche involved the issuance of 1,000,000 units at a price of $0.05 per unit, generating gross proceeds of $50,000 [2] - The funds raised will be utilized for working capital and general corporate purposes [3] Company Overview - Armory Mining is a Canadian exploration company focused on minerals critical to the energy, security, and defense sectors [4] - The company holds an 80% interest in the Candela II lithium brine project in Argentina and a 100% interest in the Riley Creek antimony-gold project in British Columbia [4] - Additionally, the company has an option to acquire a 100% interest in the Ammo antimony-gold project located in Nova Scotia [4]

Core Points - GAMMA Resources Ltd has successfully closed the first tranche of its private placement, raising gross proceeds of $651,060 [1] - The private placement consists of up to 8,333,334 units priced at $0.12 per unit, aiming for total gross proceeds of up to $1,000,000 [2] - Each unit includes one common share and one warrant, with warrants exercisable at $0.18 for 36 months [2][3] Financial Details - In the first tranche, the company issued 5,425,500 units at $0.12 each, with warrants expiring on September 5, 2028 [3] - Finders' fees amount to $13,650 in cash and 113,750 finders warrants, which have an exercise price of $0.12 for 24 months [3] Related Party Transactions - Directors of the company participated in the first tranche, acquiring a total of 417,000 shares, which is classified as a related party transaction [4] - The offering is exempt from formal valuation and minority shareholder approval requirements as it does not exceed 25% of the company's market capitalization [4] Securities Regulations - All securities from the private placement are subject to a four-month hold period and are not registered under U.S. securities laws [5] - The press release does not constitute an offer to sell or solicit offers to buy securities in the United States [5][9] Company Overview - GAMMA Resources Ltd focuses on uranium exploration and development in the U.S., with key projects in Utah and New Mexico [6] - The company aims to leverage favorable market conditions and policy changes in the U.S. nuclear sector to provide responsibly sourced uranium [6]

Core Viewpoint - Bathurst Metals Corp. has entered into an agreement to acquire a 100% interest in the Merry May Project, a mineral claim in British Columbia, which is expected to enhance its gold exploration portfolio [1][3]. Acquisition Details - The acquisition involves an Assignment and Assumption Agreement dated September 4, 2025, for a mineral claim of 81.6 hectares near Gold Bridge, B.C. [1] - As part of the agreement, Bathurst will issue 2,200,000 common shares to the vendor, pending approval from the TSX Venture Exchange [1]. - The Company will reimburse the vendor $1,000 upon receiving TSXV approval and must incur at least $50,000 in expenditures on the claim within 24 months to exercise the option [2]. Financial Terms - The claim will be subject to a net smelter royalty of 1.0% in favor of the underlying optionor, which Bathurst can purchase for $1,000,000 after the commencement of commercial production [2]. Strategic Importance - The CEO of Bathurst highlighted that the Merry May Project is located in a highly prospective area for gold mineralization, which allows for year-round development activities [3]. Additional Information - The Company also reported the payment of finders' fees amounting to $7,175 related to a recent private placement [4]. - Lorne Warner, a qualified person, has reviewed and approved the scientific and technical disclosures in the news release [5].

Core Viewpoint - Vanguard Mining Corp. has terminated its agreement with American Salars Lithium Inc. regarding the sale of the Pocitos 1 Lithium Salar Project, allowing the company to retain full ownership and exploration potential of the project [1][3]. Company Summary - The Pocitos 1 Lithium Salar Project is an 800-hectare lithium brine property located in Salta Province, Argentina, which is part of a prolific lithium brine district [1][6]. - The agreement with American Salars was initially announced on June 17, 2024, and included an inferred lithium carbonate equivalent (LCE) mineral resource estimate [2]. - The termination was due to American Salars' failure to meet local government payment obligations and other creditor responsibilities [3]. - Vanguard's President and CEO, David Greenway, emphasized that regaining control of Pocitos 1 protects shareholder interests and maintains exposure to a valuable lithium project [4]. Industry Summary - Lithium carbonate prices in China have recently rebounded to approximately CNY 78,720 per tonne (US$10,957/tonne), reflecting a more than 25% increase over the past month [5]. - The Pocitos 1 project is situated in a region that accounts for over 50% of the world's lithium brine resources, highlighting its global significance [6]. - Argentina has become a key player in the lithium market, with over US$14 billion invested by international companies in the past three years, driven by favorable geological conditions and supportive policies [12]. - The province of Salta is recognized as a favorable mining jurisdiction, attracting significant investment and project development [13][16]. - Global lithium demand is projected to triple by 2035, driven by the growth of electric vehicles and renewable energy systems [14].

Core Viewpoint - Helix BioPharma Corp. has decided not to proceed with the previously announced equity draw-down subscription facility with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited due to a misalignment with its capital strategy and long-term shareholder value objectives [1][2]. Group 1: Financing Decision - The company entered into a non-binding term sheet with GEM on October 15, 2024, and received shareholder approval for the financing arrangement on March 26, 2025 [2]. - After evaluating market conditions and corporate objectives, Helix concluded that the GEM facility no longer aligns with its capital strategy [2]. - The letter of intent with GEM expired, and the company has chosen not to execute binding agreements or pursue financing with them [2]. Group 2: Future Financing Plans - Helix is actively engaging in discussions with financial partners to explore alternative financing structures that better align with its strategic direction [3]. - The company remains committed to securing the necessary capital to advance its clinical programs and achieve corporate objectives [3]. Group 3: Company Overview - Helix BioPharma is focused on developing innovative solutions for hard-to-treat cancers, with its pipeline led by Tumor Defense Breaker™ L-DOS47, which targets CEACAM6-expressing tumors [4]. - L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and is part of a broader strategy that includes next-generation bi-specific antibody-drug conjugates [4]. - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug [4].

Core Viewpoint - CHARBONE Hydrogen Corporation has signed an Asset Purchase Agreement to acquire operational hydrogen production and refuelling equipment in Quebec, which will expedite the commissioning of its Sorel-Tracy facility and enable the company to produce and deliver its first industrial high purity hydrogen sales in the upcoming quarter [1][8]. Group 1: Acquisition and Financial Position - The acquisition involves dismantling, repurposing, and relocating existing equipment to Sorel-Tracy, which will reduce installation costs and allow for production by early Q4 2025 [2][4]. - CHARBONE has secured a non-dilutive USD 50 million construction capital facility, enhancing its capital position and ability to scale its development plan [2]. - The company has completed a $1 million non-brokered private placement, with $0.5 million already secured to accelerate the completion of its flagship facility [3][5]. Group 2: Operational Progress and Strategy - The grid connection and water connection necessary for hydrogen production have been completed, indicating significant operational progress [4]. - The acquisition is structured to preserve cash flow, with part of the purchase price paid in CHARBONE stock and the remainder in cash over two years [4][7]. - This strategic move positions CHARBONE to deliver green and high purity hydrogen to industrial customers more quickly, leveraging proven operating equipment [7][8]. Group 3: Market Position and Future Outlook - The acquisition marks a turning point for CHARBONE, allowing the company to generate its first hydrogen revenues and capture early-mover advantages in the North American green hydrogen market [8]. - CHARBONE is focused on developing a modular network for green hydrogen production while partnering with industry players to diversify revenue streams and reduce risks [9].

Core Viewpoint - Allegiant Gold Ltd. has successfully closed a C$10.5 million private placement, primarily led by Kinross Gold Corporation, which increases Kinross's equity ownership in Allegiant to 9.9% on a partially diluted basis, enabling the company to advance its Eastside project over the next 2-3 years [1][4]. Financing Details - The Offering involved the issuance of 21,000,000 units at a price of C$0.50 per unit, with each unit comprising one common share and one-half of a common share purchase warrant [2]. - Each warrant allows the holder to acquire an additional common share at a price of C$0.70 for 18 months from issuance, with provisions for accelerated expiry if the share price exceeds CDN$1.00 for ten consecutive trading days [2][3]. Use of Proceeds - Proceeds from the Offering will fund Allegiant's multi-year development plan at the Eastside Project, including a comprehensive geophysics and mapping campaign, up to 20,000 meters of drilling, targeting new high-grade zones, and advancing towards future technical and economic milestones [6]. Financial Position - The financing positions Allegiant strongly for the next three years, with over $13 million in capital available to accelerate exploration and enhance resource quality [5][7]. - The 12-month hold period for securities issued reflects investor confidence and aims to create an equal footing for all investors, particularly U.S. investors [6]. Insider Participation - Certain insiders subscribed for a total of 97,300 units in the Offering, amounting to gross proceeds of $48,650, which is classified as a related party transaction [9]. Company Overview - Allegiant Gold owns three gold projects in Nevada, with the Eastside project being the flagship, hosting a large and expanding gold/silver resource [10].

TORONTO, Ontario – September 5, 2025 – TheNewswire - LAURION Mineral Exploration Inc. (TSXV: LME | OTCPINK: LMEFF) (“LAURION” or the “Corporation”) is pleased to provide this corporate update on its previously announced advisory engagements, exploration progress, and investor outreach initiatives. Reference is made to the Corporation’s press releases dated August 19, 2025, June 2, 2025, May 27, 2025 and May 8, 2025.  Advisory Network ExpansionAmid growing shareholder interest and evolving market access str ...

Company Overview - Universal Ibogaine Inc. (UI) is a life sciences company focused on transforming addiction treatment using medicalized ibogaine, specifically targeting opioid use disorder through a planned clinical trial in Canada [4] - The company is also developing a holistic addiction treatment protocol at its Kelburn Recovery Centre, aimed at revolutionizing addiction treatment and improving the lives of affected individuals and families [4] Clinical Trial Announcement - UI intends to file a Clinical Trial Application (CTA) with Health Canada within 90 days to investigate ibogaine as a treatment for opioid use disorder [1] - The company has secured a reliable supply of pharmaceutical-grade ibogaine, produced in compliance with Good Manufacturing Practice (GMP) standards, ensuring quality and safety for the clinical trial [2] Leadership Statement - CEO Nick Karos emphasized the company's commitment to advancing innovative addiction therapies and expressed confidence in conducting rigorous clinical studies focused on patient safety and therapeutic effectiveness [3]

Core Points - The company will change its name from Orion Nutraceuticals Inc. to Pinetree Ventures Corp. effective September 9, 2025 [1] - A share consolidation will occur, with a ratio of one post-Consolidation Share for every twenty-five pre-Consolidation Shares [2] - The total number of issued and outstanding Shares will decrease from 29,307,965 to approximately 1,172,318 post-Consolidation [3] - The new CUSIP number for the Shares will be 723328209 and the new ISIN number will be CA7233282093 [4] - No fractional Shares will be issued; fractions will be rounded down to the nearest whole Share [5] - The company is actively reviewing investment opportunities across multiple sectors to enhance shareholder value [6]